November 1, 2018Open Access

Efficacy and safety of rituximab in childhood-onset, difficult-to-treat nephrotic syndrome

Key Points

Key points are not available for this paper at this time.

Abstract

RTX administration was safe and effective in patients with difficult-to-treat NS. One or 2 doses of RTX may be sufficient to deplete B cells and achieve better control of pediatric NS.

Efficacy and safety of rituximab in childhood-onset, difficult-to-treat nephrotic syndrome

Key Points

Abstract

Cite This Study